NUP153 and paraganglioma: Preclinical validation showed that X4.5dianilinophthalimide significantly suppressed NUP153 activity in adrenal cortical carcinoma (ACC), pheochromocytoma and paraganglioma (PCPG), and READ, while Imatinib exhibited similar inhibitory effects in STAD (Figure 8C).